Evidence map›Paper›PMID 40623897›Full record

ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2025

[Chinese expert consensus on the diagnosis and treatment of adult Langerhans cell histiocytosis (2025)].

Hematological Rare Disease Academic Group, Hematology Committee of Chinese Medical Association, China Langerhans cell histiocytosis Network

Abstract readConsensus StatementEnglish Abstract
In one paragraph

Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Hematological Rare Disease Academic Group, Hematology Committee of Chinese Medical Association
China Langerhans cell histiocytosis Network

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Langerhans cell histiocytosis (LCH) is a clonal hematologic neoplasm primarily characterized by the activation of the mitogen-activated protein kinase (MAPK) signaling pathway; it can involve any organ or system and presents with diverse clinical manifestations. Based on current evidence-based medicine and combined with domestic clinical experience, this consensus elaborates on the pathogenesis, clinical manifestations, diagnosis, treatment, and efficacy evaluation of adult LCH, aiming to provide professional guidance for its diagnosis and treatment in China.

Indexed as

Histiocytosis, Langerhans-CellAdultChinaConsensusEvidence-Based MedicineHumans

Identifiers

PMID40623897
PMCPMC12268291

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.